CYFRA21―1CEANSE和CA125联合检测在非小细胞肺癌中诊断价值.docVIP

CYFRA21―1CEANSE和CA125联合检测在非小细胞肺癌中诊断价值 　　【摘要】 目的：探讨细胞角蛋白19片段（CYFRA21-1）、癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）、糖类抗原125（CA125）联合检测在非小细胞肺癌（NSCLC）中的诊断价值。方法：选取2010年1月-2015年6月本院收治的NSCLC患者92例和肺部良性病变患者95例作为研究对象，92例NSCLC患者根据病理类型的不同分为肺鳞癌组42例和肺腺癌组50例。采用电化学发光法测定所有患者的CYFRA21-1、CEA、NSE及CA125水平。结果：NSCLC组CYFRA21-1、CEA、NSE及CA125均明显高于肺部良性病变组，两组比较差异均有统计学意义（P0.05）。肺鳞癌以CYFRA21-1敏感性和特异性最高，分别为71.40%和89.10%；肺腺癌以CEA敏感性及特异性最高，分别为60.00%和84.30%。CYFRA21-1对NSCLC诊断的敏感性为46.53%，特异性为85.26%；CEA对NSCLC诊断的敏感性为42.58%，特异性为81.05%；NSE对NSCLC诊断的敏感性为57.43%，特异性为76.85%；CA125对NSCLC诊断的敏感性为48.51%，特异性为66.32%；四项指标联合检测则敏感性为93.26%，特异性为98.25%。结论：CYFRA21-1、CEA、CA125和NSE对NSCLC的早期发现、早期诊断具有一定价值，四者联合检测有明显的互补性，可以显著提高NSCLC的诊断率。 　　【关键词】 细胞角蛋白19片段； 癌胚抗原； 神经元特异性烯醇化酶； 糖类抗原125； 非小细胞肺癌 　　【Abstract】 Objective：To discuss the diagnostic value of combined detection of CYFRA21-1，CEA，NSE and CA125 in non small cell lung cancer.Method：92 cases of NSCLC and 95 cases of lung benign lesions from January 2010 to June 2015 in our hospital were selected as the research objects，92 cases of NSCLC were divided into 42 cases of lung squamous cell carcinoma group and 50 cases of lung adenocarcinoma group according to the different pathological types.The levels of CYFRA21-1， CEA， NSE and CA125 in all patients were measured by electrochemical luminescence method.Result：The CYFRA21-1，CEA，NSE and CA125 in NSCLC group were significantly higher than those in benign lung disease group，the differences were statistically significant（P0.05）.The sensitivity and specificity of CYFRA21-1 were respectively 71.40% and 89.10% in lung squamous cell carcinoma group，the sensitivity and specificity of CEA were respectively 60.00% and 84.30% in lung adenocarcinoma group.The sensitivity of CYFRA21-1 in the diagnosis of NSCLC was 46.53%，specificity was 85.26%.The sensitivity of CEA in the diagnosis of NSCLC was 42.58%，specificity was 81.05%.The sensitivity of NSE in the diagnosis of NSCLC was 57.43%，specificity was 76.85%.The sensitivity of CA125 in the diagnosis of NSCLC was 48.51